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Abstract 
The management of  severe traumatic 
brain injury still represents a challenge for 
the neurosurgeons and neurointensivist 
specialists. The central aim of the therapy is 
lowering the intracranial pressure. There 
are many ways of accomplishing this goal, 
by means of medical or surgical treatment. 
This article is a review of the papers and 
guidelines in the literature regarding the 
control of the elevated intracranial pressure.  
Keywords: severe traumatic brain 
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Introduction 
The intracranial pressure (ICP) refers to 
the compartment inside the skull - since the 
brain is almost completely incompressible 
and the skull is a rigid structure with only 
one outlet (the formaen magnum), 
expansion of the volume in any component 
within the skull causes an increase in the 
pressure of the cranial compartment.  
The principles of increased intracranial 
pressure are defined by the modified 
Monro-Kellie doctrine: the normal 
components within the intracranial space 
are the brain, blood, and cerebrospinal fluid 
(CSF). To these three sometimes is added a 
mass lesion such as a hematoma or a tumor 
which can also contribute to the volume of 
the intracranial space. 
An increase in the volume of one of the 
components contained within the 
intracranial space can occur only at the 
expense of the other components. As the 
volume of edema in the brain or an 
expanding mass lesion increases, initially 
the CSF volume decreases, then the blood 
volume decreases. Continued expansion of 
intracranial volume after these 
compensatory mechanisms are exhausted 
causes a rapid increase in ICP and 
herniation of the brain. 
Monitoring the intracranial pressure 
Due to specific technical problems, 
sometimes arise the question – when, how 
and which patients need monitoring of the 
ICP, not mentioning the costs of the 
procedure? Generally admittance is that 
patients having suffered mild / moderate head 
injuries (Glasgow Coma Scale (GCS) 9 to 15) 
do not undergo ICP monitoring. However, 
patients with severe head injuries (GCS 8 to 
3) have a significant chance of developing 
intracranial hypertension which varies from 5 
% to 67% with the descent of GCS [1]. 
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According to data from Brain Trauma 
Foundation, published in 2007 [2]: 
- there are insufficient data for 
recommending level I indications (based on 
good quality randomized control trials 
(RCT’s)) 
- level II (moderate quality RCT’s) – 
ICP should be monitored in all salvageable 
patients with a severe TBI in terms of GCS 
and an abnormal CT scan (considering 
hematomas, contusions, swelling, 
herniations or compressed basal cisterns)  
-level III (poor quality RCT’s, moderate 
or poor quality cohorts) – ICP monitoring 
is indicated in patients with severe TBI, 
normal CT scan but two or more of the 
followings noted on admission : age over 
40, unilateral or bilateral posturing, systolic 
blood pressure < 90 mm Hg 
To these are added some of the 
neurointensivists recommendations, 
whenever possible in comatose patients 
with intracranial lesions : malignant sylvian 
infarction, acute hydrocephalus after 
aneurismal SAH, due to the direct data on 
ICP offered. 
The gold standard for monitoring ICP is 
a ventriculostomy catheter inserted through 
a burr hole into one of the lateral ventricles. 
The ventriculostomy catheter is connected 
to a drainage system and can be used to 
monitor the ICP through a fluid-coupled 
external pressure transducer. This system 
provides the most accurate measurement of 
ICP and is stable over time. A 
ventriculostomy catheter will also allow 
drainage of CSF for control of ICP. 
Problems associated with ventriculostomy 
catheters include blockage of the catheter, 
displacement of the catheter from the 
ventricle, and infection. Antibiotic-
impregnated ventriculostomy catheters 
reduce the risk of infection from 9.4% to 
1.3% [3]. 
Other invasive monitors for ICP include 
intraparenchymal, subdural, and epidural 
monitors. These probes use either a strain 
gauge or a fiberoptic probe. These probes 
require zeroing prior to insertion and are 
subject to drift over time. Of these probes, 
intraparenchymal probes are the most 
accurate with the least amount of drift. The 
advantage of these probes is that they do 
not have to be inserted into the ventricle, 
which may be difficult to locate if it is 
collapsed or if there is significant midline 
shift. 
A problem in ICP monitoring arises 
from the fact that ICP is not identical 
throughout all the intracranial space. From 
patients with bilateral symmetric  
transducers but lesion in one hemisphere, 
the difference between the 2 sensors can be 
up to 25 mm Hg, especially for acute SDH 
or contusions[4]  
The intracranial pressure as a function of 
increasing volume in the intracranial space 
is a nonlinear function (figure 1) . Early 
increases in volume of a mass lesion result 
in displacement of CSF from the cranial 
compartment into the spinal compartment 
and cause little increase in ICP. Once the 
maximal amount of CSF has been displaced 
from the intracranial compartment, the ICP 
increases rapidly. 
Cerebral Perfusion  
Cerebral perfusion pressure (CPP) is 
defined as the mean arterial pressure 
(MAP) minus the ICP and is the driving 
pressure for cerebral blood flow (CBF).  
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Figure 1 The relationship between intracranial 
pressure and volume 
 
Pressure autoregulation is the intrinsic 
ability of the cerebral vasculature to 
maintain flow constant over a wide range of 
CPP values. Normally, the brain is able to 
autoregulate and to maintain an adequate 
CBF at CPP values ranging from 50 to 140 
mm Hg. However, dynamic pressure 
autoregulation is commonly dysfunctional 
in the injured brain . When pressure 
autoregulation is impaired, the lower limit 
of autoregulation can be shifted upward 
from 50 to 60 to 90 mm Hg [5]. When 
pressure auto regulation is entirely absent, 
perfusion passively follows CPP. This loss 
of normal autoregulation requires careful 
maintenance of a sufficient MAP and 
adequate control of ICP to avoid 
hypoperfusion of the brain. Extremely 
elevated MAP should also be avoided as it 
can cause increased ICP. 
The influence of CPP relies in its 
influence on patients outcome: in traumatic 
comatose patients with ICP over 20 mm 
Hg, the maximizing of CPP over 70 mm 
Hg leaded to a mortality of only 29% with 
over 80% of the survivors with no or 
minimal neurological deficits [6]. To 
maintain such perfusion, aggressive CSF 
drainage was used, together with an 
association of vasopressors : phenylephrine 
max. 4ug/kg/min, norepinephrine max. 0.2-
0.4 ug/kg/min and dopamine at renal 
protection dose. The authors suggest that 
there is no tendency for high CPP to 
potentate elevated intracranial pressure. 
To this maximal CPP theory is opposed 
“the LUND concept”[7] from Sweden 
considering that maintaining CPP at high 
values may result in vasogenic edema by 
transudation of fluid through the altered 
vasculature of the brain. This transcapillary 
leakage together with inotropic stimulation 
results in vasodilatation and interstitial 
edema which contributes in raising the 
ICP. According to them, reduction of ICP 
must be realized with a combination of low 
dose thiopental (1-3 mg/kg/h) , fentanyl (2-
5 ug/kg/h) and dihydroergotamine (0.1-0.9 
ug/kg/h infusion) which acts like a 
precapillary and large vein vasoconstrictor. 
Metoprolol as β1 antagonist and α2 agonist 
clonindine may be added to reduce 
medium arterial pressure to normal age-
indexed values. Fluid balance is maintained 
slight negative. While the LUND therapy 
achieved excellent survival ( 49/53 comatose 
patients, 92%) and recovery (85% had GOS 
4 and 5), there are no actually randomized 
studies to compare the two strategies[8]. 
Brain metabolism  
Indirectly connected to the perfusion of 
the brain is the way the cerebral tissue 
utilizes glucose and oxygen provided.  
The insertion of a brain tissue pO2 probe 
allows continuous monitoring of 
oxygenation in a local region of the brain. 
The location of the probe is critical and 
determines the nature of the pO2 
information that will be obtained. If the 
probe is inserted near a focal lesion, 
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oxygenation can be monitored in the tissue 
at greatest risk should the injury expand. 
Insertion of the probe in uninjured brain 
allows monitoring of a local area that 
should be representative of the overall less-
injured oxygenation status of the brain. 
Normal values and critical threshold values 
for PbO2 are somewhat less accepted. In 
normal anesthetized subjects, PbO2 in 
normal brain ranges from 20 to 40 mm Hg. 
Recent studies comparing PbO2 values to 
PET measurements of oxygen extraction 
fraction (OEF) found that the PbO2 value 
associated with an OEF of 40% (the mean 
value for OEF in normal subjects) was 14 
mm Hg [9]. Values of PbO2 that indicate 
tissue hypoxia / ischemia are probably 
considerably less than 14 mm Hg.  
Prospective studies have demonstrated 
that PbO2 less than 15 mm Hg is associated 
with poor outcome. Some studies have 
suggested that a treatment protocol aimed at 
keeping brain pO2 higher than 25 mm Hg 
may reduce mortality when compared to 
patients treated similarly with no brain pO2 
probe[10]. 
Jugular venous oxygen saturation 
(SjvO2) can be measured by inserting a 
catheter into the internal jugular vein and 
advancing it to the skull base. This allows 
measurement of the oxygen saturation of 
the blood exiting the brain, which provides 
information on the adequacy of cerebral 
blood flow and oxygen delivery to the 
brain. Fiberoptic continous  oxygen 
saturation monitoring or frequent jugular 
blood sampling are used to compute the 
cerebral oxygen consumption: 
 
CMR O2 = CBF x difference [Conc Art. O2 – 
Conc.Jug.Vein O2] 
 
Use of SjvO2 and of the cerebral 
metabolic rate allow an assessment of both 
brain hemodynamic reserve and its 
metabolic resolution, limiting potentially 
deleterious side effects of therapeutic 
interventions aimed at ICP control. SjvO2 
is normally between 55-75% and a value 
less than 50% suggest the use of a therapy 
aimed at increasing oxygen delivery (raising 
CBF, ventilation). As long as SjvO2 remains 
at normal values, it allows the decrease of 
CPP to lower levels and consecutive ICP, 
by increasing the ventilation level and 
diminishing PaCO2.  
Episodes of jugular venous oxygen 
desaturation are associated with worse 
neurologic outcome. Increased SjvO2 may 
indicate decreased oxygen uptake in the 
brain. The major limitation of SjO2 
monitoring is that it cannot detect local 
ischemia within the brain. Serial 
measurements of both SjvO2 and PbO2 
suggest that a PbO2 of 8.5 mm Hg indicates 
a similar level of oxygenation as a SjvO2 of 
50% [11]. 
Treatment thresholds 
As it has become possible to measure 
additional brain-specific physiologic 
parameters in the ICU, different 
management strategies have evolved that 
place special emphasis on parameters other 
than ICP.. However, all of these 
physiologic parameters are related to 
outcome, and there is no clear evidence that 
one parameter is more important than the 
others. The best circumstance occurs when 
ICP, CPP, and brain oxygenation are all 
maintained in normal ranges, and this 
should probably be the goal of 
management. When this is not possible, it is 
important to understand the limitations of 
each of the monitors when making 
therapeutic decisions. Additionally, clinical 
studies are needed to demonstrate what 
management strategies may best improve 
neurologic outcome. 
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Table 1 
Normal values and treatment thresholds 
for physiologic parameters [12] 
 NORMAL 
TREATMENT 
THRESHOLD 
ICP 0-10 mm Hg 20-25 mmHg 
CPP 50 mm Hg 60 mm Hg 
SjvO2 55-75% 50% 
PbO2 20-40 mm Hg 8-10 mm Hg 
Principles of therapy of elevated 
intracranial pressure 
A thorough examination by a 
neurointensivist is mandatory, despite the 
fact that the patient has been already 
examined by the neurologist / 
neurosurgeon. Particular attention must be 
given to the ABC of resuscitation: stability 
and validity of endotracheal tube, 
ventilation status, arterial blood samples, 
cardiac rhythm and hemodynamic 
adequacy. Also should be considered the 
possibly iatrogeniccaly worsened cerebral 
edema by intravenous fluid at high rate or 
inappropriate, other injuries that may have 
escaped at the first examination in the 
Emergency Dept. or neurological status 
aggravated since the first examination. 
General measures 
Specific factors that may aggravate 
intracranial hypertension include 
obstruction of venous return (head 
position, agitation), respiratory problems 
(airway obstruction, hypoxia, hypercapnia), 
fever, severe hypertension, hyponatremia, 
anemia, and seizures. Routine critical care 
management of the patient at risk for 
intracranial hypertension should include 
measures to prevent these factors.  
•Positioning - while elevation of the 
head in order to lower the ICP is a well 
known principle, only later was found that 
while ICP does not significantly decrease 
when raising from 10 to 45 degrees, CPP, 
CVP and blood systolic pressure did 
diminish[13]. Among other studies, the 
best option appear to maintain only a slight 
elevation, 15-30 degrees, which has little or 
no effect on CBF and CPP, with the head 
in neutral position to minimize the decrease 
in jugular venous outflow 
•Sedation and neuroparalysis - sedation 
with Propofol (10-100 ug/kg/min) is 
preferred to neuromuscular block because 
it can be quick and completely reversed in 
minutes. Other sedatives can be used as 
well as short acting benzodiazepine 
Midazolam or longer acting Lorazepam, but 
Propofol is preferred due to its fast-off 
properties, that allow a patient to be sedated 
and awakened when necessary, not to 
mention its possible neuroprotective action. 
If sedatives alone are not capable of 
controlling an agitated patient, a 
neuromuscular blocking agent can be added 
(Atracurium or Pancuronium). 
•Maintain normoglycemia - in any 
cerebral lesion, hyperglycemia (>150 
mg/dL) has been noted to worsen outcome, 
through decreased oxidative metabolism in 
local ischemic areas, increase lactate 
production and cellular disfunctions. 
Ischemic strokes need an even tighter 
control [14] 
•Hyperventilation - therapy is based on 
the idea that a decrease in paCO2 , from 30 
to 35 mm Hg, can reduce intracranial 
pressure by constricting cerebral blood 
vessels and reducing cerebral blood volume, 
effects mediated by the change in pH 
induced in the extracellular fluid. The 
effects of hyperventilation on ICP are 
immediate, but the duration of the effect is 
brief because the pH of the brain, at least in 
normal individuals, soon equilibrates to the 
lower pCO2 level. After several 
studies[15,16], despite good initial results, 
no significant improve in outcome was 
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found at 6-12 months ( even with THAM 
to resolve CSF acidosis or clinical 
introduction of SjvO2 to evaluate exaggerate 
hyperventilation to paCO2 of 25-30 mm 
Hg) with long-term hyperventilation, even 
worse outcomes after traumatic brain 
injury, possibly secondary to reduction in 
CBF. The concomitant adverse effect of  
progressive decreasing PbO2 in the first 5 
days[17] make hyperventilation to be used 
only as a short-term therapeutic 
intervention, only to control acute increase 
of the ICP after the first 24 hours after 
injury [18] 
•Osmotic therapy - one of the mainstays 
of treatment of elevated ICP is osmotic 
therapy with either mannitol or hypertonic 
saline. This treatment can be initiated prior 
to insertion of an ICP monitor if signs and 
symptoms of herniation are present. 
The effects of mannitol  are correlated to 
its hyperosmolality, creating an osmolar 
gradient between the vascular space and the 
normal brain tissue space, whilst in lesional 
areas the membrane pump failure prevents 
partially the movement of water. The initial 
bolus is 0.25-0.5 g/kg - in the first 10 
minutes there is an improvement of CBF 
due to the plasma expansion and improved 
blood fluidity, then at 30-60 minutes a 
decrease in ICP and cerebral brain volume. 
The use of small bolus dosages decreases 
the daily total dose when compared to 
continuous administration. Care should be 
taken to maintain serum osmolality below 
320 mOsm, by checking serum sodium 
levels every 8 hours (max of 150 mEq/l) and 
avoid hypovolemia in order to prevent renal 
failure. The prolonged use of mannitol over 
3 days or in severe lesions with blood-brain 
barrier destroyed may lead to aggravation of 
cerebral edema by penetration of mannitol 
in the interstitial space [19]. 
Although mannitol has been more 
widely studied, there are studies suggesting 
that hypertonic saline is more effective at 
lowering intracranial pressure. These 
studies have been small and have not 
demonstrated a statistically significant 
difference in outcome. The usual dose form 
is boluses of 7.5% hypertonic saline [20]. 
Other agents that are under investigation 
include hypertonic saline hetastarch, with 
studies to compare bolus doses of 7.2% 
hypertonic saline hetastarch 200/0.5 with 
15% mannitol or 7.5% hypertonic saline/6% 
dextran solution to bolus dosing of 20% 
mannitol. Both studies showed improved 
reduction of ICP over mannitol but no 
difference in outcome [12,21]. 
•Steroids - several randomized, 
controlled studies have demonstrated no 
benefit in treating patients with traumatic 
brain injury with steroids. The recently 
completed Corticosteroid Randomization 
After Significant Head injury (CRASH) 
trial observed an increased risk of death in 
patients receiving methylprednisolone for 
48 hours after injury [22]. Steroids are also 
not recommended for treatment of the 
cellular edema accompanying stroke. 
Steroids can be useful in treating vasogenic 
edema associated with brain tumors or 
selected parasitic infections.  
•Last theoretic options - hypothermia 
and barbiturates. While hypothermia is 
seldom used due to its uncertain effects 
besides lowering ICP (increased 
coagulability, increased rate of infections), 
barbiturates are used sometimes in order to 
decrease CMRO2 and inhibition of free 
radicals. To achieve a barbituric coma and 
burst suppression on EEG the loading dose 
of 10 mg/kg intravenously (IV) over 30 
minutes is followed by 5 mg/kg per hour 
for three doses and maintenance dose of 1 
mg/kg per hour, with continuous EEG 
monitoring if available. However 
pentobarbital coma is associated with 
significant morbidity, mainly hypotension 
which require concomitant administration 
of vasopressors, high risk of pneumonia, 
pressure ulcers, and paralytic ileus. 
•Non ICU options are those provided 
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by neurosurgeons - removal of CSF by 
ventricular drainage or decompressive 
craniectomy. 
Conclusions 
High ICP can be caused by several 
lesions, including stroke, subarachnoid 
hemorrhage, mass lesion, hydrocephalus, 
and trauma. Initial management is focused 
on maintaining oxygenation and perfusion 
using the ABCs of resuscitation. If signs of 
herniation are present, an initial bolus of 
mannitol should be given. A 
ventriculostomy catheter should be inserted 
to allow monitoring of ICP. Treatment 
should be initiated with the goal of 
maintaining ICP below 20 to 25 mm Hg 
and the CPP at 60 mm Hg. Initial 
treatments of elevated ICP include sedation 
and paralysis, drainage of CSF, mild 
hyperventilation, and bolus administration 
of osmotic agents such as mannitol. If ICP 
is not controlled with these measures, 
additional treatments including 
pentobarbital coma, hypothermia, or 
decompressive craniectomy can be 
considered. Last problem is that high ICP 
for a stroke or traumatic brain injury may 
be a normal ICP in brain tumors or chronic 
hydrocephalus. 
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